Skip to main content
Top
Published in: Cardiovascular Diabetology 1/2014

Open Access 01-12-2014 | Original investigation

Does glycemic control reverse dispersion of ventricular repolarization in type 2 diabetes?

Authors: Takayuki Miki, Toshiyuki Tobisawa, Tatsuya Sato, Masaya Tanno, Toshiyuki Yano, Hiroshi Akasaka, Atsushi Kuno, Makoto Ogasawara, Hiromichi Murase, Shigeyuki Saitoh, Tetsuji Miura

Published in: Cardiovascular Diabetology | Issue 1/2014

Login to get access

Abstract

Background

Abnormal ventricular repolarization is a predictor of cardiovascular mortality. In this study, we tested the hypothesis that glycemic control reverses abnormal ventricular repolarization in patients with type 2 diabetes.

Methods

We analyzed longitudinal changes in repolarization indices of electrocardiograms in retrospectively enrolled 44 patients with type 2 diabetes and 44 age-matched healthy subjects.

Results

In the diabetic group, BMI was greater, levels of HbA1c (10.0 ± 1.6 vs. 5.6 ± 0.3%) and triglyceride were higher and level of HDL cholesterol was lower than those in the control group. Although mean QTc intervals were similar (413.6 ± 18.5 vs. 408.3 ± 22.7 ms), QT dispersion (41.8 ± 15.4 vs. 28.7 ± 7.7 ms) and Tpeak-Tend in lead V5 (83.6 ± 13.6 vs. 71.3 ± 10.3 ms) were significantly longer in the diabetic group than in the control group, indicating increased heterogeneity of ventricular repolarization in type 2 diabetes. During follow-up of 36 patients in the diabetic group for 787 ± 301 days, HbA1c level decreased to 7.3 ± 1.6%, while BMI did not significantly change. In contrast to HbA1c, QT dispersion (45.8 ± 15.0 ms) and Tpeak-Tend in lead V5 (83.6 ± 10.6 ms) were not significantly reduced during the follow-up period. There was no correlation between the change in HbA1c and the change in QT dispersion or Tpeak-Tend.

Conclusions

Increased heterogeneity of ventricular repolarization in type 2 diabetic patients was not reduced during the relatively short follow-up period despite significantly improved glycemic control.
Appendix
Available only for authorised users
Literature
1.
go back to reference IDF Diabetes Atlas. 2013, International Diabetes Federation, Brussels, Belgium IDF Diabetes Atlas. 2013, International Diabetes Federation, Brussels, Belgium
2.
go back to reference Preis SR, Hwang SJ, Coady S, Pencina MJ, D’Agostino RB, Savage PJ, Levy D, Fox CS: Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation. 2009, 119: 1728-1735. 10.1161/CIRCULATIONAHA.108.829176.PubMedCentralCrossRefPubMed Preis SR, Hwang SJ, Coady S, Pencina MJ, D’Agostino RB, Savage PJ, Levy D, Fox CS: Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation. 2009, 119: 1728-1735. 10.1161/CIRCULATIONAHA.108.829176.PubMedCentralCrossRefPubMed
3.
go back to reference Miki T, Yuda S, Kouzu H, Miura T: Diabetic cardiomyopathy: pathophysiology and clinical features. Heart Fail Rev. 2013, 18: 149-166. 10.1007/s10741-012-9313-3.PubMedCentralCrossRefPubMed Miki T, Yuda S, Kouzu H, Miura T: Diabetic cardiomyopathy: pathophysiology and clinical features. Heart Fail Rev. 2013, 18: 149-166. 10.1007/s10741-012-9313-3.PubMedCentralCrossRefPubMed
4.
go back to reference Yeung CY, Lam KS, Li SW, Lam KF, Tse HF, Siu CW: Sudden cardiac death after myocardial infarction in type 2 diabetic patients with no residual myocardial ischemia. Diabetes Care. 2012, 35: 2564-2569. 10.2337/dc12-0118.PubMedCentralCrossRefPubMed Yeung CY, Lam KS, Li SW, Lam KF, Tse HF, Siu CW: Sudden cardiac death after myocardial infarction in type 2 diabetic patients with no residual myocardial ischemia. Diabetes Care. 2012, 35: 2564-2569. 10.2337/dc12-0118.PubMedCentralCrossRefPubMed
5.
go back to reference Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998, 352: 837-853. 10.1016/S0140-6736(98)07019-6. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998, 352: 837-853. 10.1016/S0140-6736(98)07019-6.
6.
go back to reference Intensive blood glucose control and vascular outcomes in patients with type 2 Diabetes. N Engl J Med. 2008, 358: 2560-2572. 10.1056/NEJMoa0802987. Intensive blood glucose control and vascular outcomes in patients with type 2 Diabetes. N Engl J Med. 2008, 358: 2560-2572. 10.1056/NEJMoa0802987.
7.
go back to reference Effects of intensive glucose lowering in type 2 Diabetes. N Engl J Med. 2008, 358: 2545-2559. 10.1056/NEJMoa0802743. Effects of intensive glucose lowering in type 2 Diabetes. N Engl J Med. 2008, 358: 2545-2559. 10.1056/NEJMoa0802743.
8.
go back to reference Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD: Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009, 360: 129-139. 10.1056/NEJMoa0808431.CrossRefPubMed Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD: Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009, 360: 129-139. 10.1056/NEJMoa0808431.CrossRefPubMed
9.
go back to reference Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I: Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013, 369: 1317-1326. 10.1056/NEJMoa1307684.CrossRefPubMed Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I: Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013, 369: 1317-1326. 10.1056/NEJMoa1307684.CrossRefPubMed
10.
go back to reference White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F: Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013, 369: 1327-1335. 10.1056/NEJMoa1305889.CrossRefPubMed White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F: Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013, 369: 1327-1335. 10.1056/NEJMoa1305889.CrossRefPubMed
11.
go back to reference Schwartz PJ, Wolf S: QT interval prolongation as predictor of sudden death in patients with myocardial infarction. Circulation. 1978, 57: 1074-1077. 10.1161/01.CIR.57.6.1074.CrossRefPubMed Schwartz PJ, Wolf S: QT interval prolongation as predictor of sudden death in patients with myocardial infarction. Circulation. 1978, 57: 1074-1077. 10.1161/01.CIR.57.6.1074.CrossRefPubMed
12.
go back to reference Zhang Y, Post WS, Blasco-Colmenares E, Dalal D, Tomaselli GF, Guallar E: Electrocardiographic QT interval and mortality: a meta-analysis. Epidemiology. 2011, 22: 660-670. 10.1097/EDE.0b013e318225768b.PubMedCentralCrossRefPubMed Zhang Y, Post WS, Blasco-Colmenares E, Dalal D, Tomaselli GF, Guallar E: Electrocardiographic QT interval and mortality: a meta-analysis. Epidemiology. 2011, 22: 660-670. 10.1097/EDE.0b013e318225768b.PubMedCentralCrossRefPubMed
13.
go back to reference Montanez A, Ruskin JN, Hebert PR, Lamas GA, Hennekens CH: Prolonged QTc interval and risks of total and cardiovascular mortality and sudden death in the general population: a review and qualitative overview of the prospective cohort studies. Arch Intern Med. 2004, 164: 943-948. 10.1001/archinte.164.9.943.CrossRefPubMed Montanez A, Ruskin JN, Hebert PR, Lamas GA, Hennekens CH: Prolonged QTc interval and risks of total and cardiovascular mortality and sudden death in the general population: a review and qualitative overview of the prospective cohort studies. Arch Intern Med. 2004, 164: 943-948. 10.1001/archinte.164.9.943.CrossRefPubMed
14.
go back to reference Okin PM, Devereux RB, Lee ET, Galloway JM, Howard BV: Electrocardiographic repolarization complexity and abnormality predict all-cause and cardiovascular mortality in diabetes: the strong heart study. Diabetes. 2004, 53: 434-440. 10.2337/diabetes.53.2.434.CrossRefPubMed Okin PM, Devereux RB, Lee ET, Galloway JM, Howard BV: Electrocardiographic repolarization complexity and abnormality predict all-cause and cardiovascular mortality in diabetes: the strong heart study. Diabetes. 2004, 53: 434-440. 10.2337/diabetes.53.2.434.CrossRefPubMed
15.
go back to reference Cox AJ, Azeem A, Yeboah J, Soliman EZ, Aggarwal SR, Bertoni AG, Carr JJ, Freedman BI, Herrington DM, Bowden DW: Heart rate-corrected QT interval is an independent predictor of all-cause and cardiovascular mortality in individuals with type 2 diabetes: the diabetes heart study. Diabetes Care. 2014, 37: 1454-1461. 10.2337/dc13-1257.PubMedCentralCrossRefPubMed Cox AJ, Azeem A, Yeboah J, Soliman EZ, Aggarwal SR, Bertoni AG, Carr JJ, Freedman BI, Herrington DM, Bowden DW: Heart rate-corrected QT interval is an independent predictor of all-cause and cardiovascular mortality in individuals with type 2 diabetes: the diabetes heart study. Diabetes Care. 2014, 37: 1454-1461. 10.2337/dc13-1257.PubMedCentralCrossRefPubMed
16.
go back to reference Cardoso CR, Salles GF, Deccache W: Prognostic value of QT interval parameters in type 2 diabetes mellitus: results of a long-term follow-up prospective study. J Diabetes Complications. 2003, 17: 169-178. 10.1016/S1056-8727(02)00206-4.CrossRefPubMed Cardoso CR, Salles GF, Deccache W: Prognostic value of QT interval parameters in type 2 diabetes mellitus: results of a long-term follow-up prospective study. J Diabetes Complications. 2003, 17: 169-178. 10.1016/S1056-8727(02)00206-4.CrossRefPubMed
17.
go back to reference Giunti S, Gruden G, Fornengo P, Barutta F, Amione C, Ghezzo G, Cavallo-Perin P, Bruno G: Increased QT interval dispersion predicts 15-year cardiovascular mortality in type 2 diabetic subjects: the population-based Casale Monferrato Study. Diabetes Care. 2012, 35: 581-583. 10.2337/dc11-1397.PubMedCentralCrossRefPubMed Giunti S, Gruden G, Fornengo P, Barutta F, Amione C, Ghezzo G, Cavallo-Perin P, Bruno G: Increased QT interval dispersion predicts 15-year cardiovascular mortality in type 2 diabetic subjects: the population-based Casale Monferrato Study. Diabetes Care. 2012, 35: 581-583. 10.2337/dc11-1397.PubMedCentralCrossRefPubMed
18.
go back to reference Castro Hevia J, Antzelevitch C, Tornés Bárzaga F, Dorantes Sánchez M, Dorticós Balea F, Zayas Molina R, Quiñones Pérez MA, Fayad Rodríguez Y: Tpeak-Tend and Tpeak-Tend dispersion as risk factors for ventricular tachycardia/ventricular fibrillation in patients with the Brugada syndrome. J Am Coll Cardiol. 2006, 47: 1828-1834. 10.1016/j.jacc.2005.12.049.CrossRefPubMed Castro Hevia J, Antzelevitch C, Tornés Bárzaga F, Dorantes Sánchez M, Dorticós Balea F, Zayas Molina R, Quiñones Pérez MA, Fayad Rodríguez Y: Tpeak-Tend and Tpeak-Tend dispersion as risk factors for ventricular tachycardia/ventricular fibrillation in patients with the Brugada syndrome. J Am Coll Cardiol. 2006, 47: 1828-1834. 10.1016/j.jacc.2005.12.049.CrossRefPubMed
19.
go back to reference Barbhaiya C, Po JR, Hanon S, Schweitzer P: Tpeak-Tend and Tpeak-Tend/QT ratio as markers of ventricular arrhythmia risk in cardiac resynchronization therapy patients. Pacing Clin Electrophysiol. 2013, 36: 103-108. 10.1111/pace.12031.CrossRefPubMed Barbhaiya C, Po JR, Hanon S, Schweitzer P: Tpeak-Tend and Tpeak-Tend/QT ratio as markers of ventricular arrhythmia risk in cardiac resynchronization therapy patients. Pacing Clin Electrophysiol. 2013, 36: 103-108. 10.1111/pace.12031.CrossRefPubMed
20.
go back to reference Smetana P, Schmidt A, Zabel M, Hnatkova K, Franz M, Huber K, Malik M: Assessment of repolarization heterogeneity for prediction of mortality in cardiovascular disease: peak to the end of the T wave interval and nondipolar repolarization components. J Electrocardiol. 2011, 44: 301-308. 10.1016/j.jelectrocard.2011.03.004.CrossRefPubMed Smetana P, Schmidt A, Zabel M, Hnatkova K, Franz M, Huber K, Malik M: Assessment of repolarization heterogeneity for prediction of mortality in cardiovascular disease: peak to the end of the T wave interval and nondipolar repolarization components. J Electrocardiol. 2011, 44: 301-308. 10.1016/j.jelectrocard.2011.03.004.CrossRefPubMed
21.
go back to reference Panikkath R, Reinier K, Uy-Evanado A, Teodorescu C, Hattenhauer J, Mariani R, Gunson K, Jui J, Chugh SS: Prolonged Tpeak-to-tend interval on the resting ECG is associated with increased risk of sudden cardiac death. Circ Arrhythm Electrophysiol. 2011, 4: 441-447. 10.1161/CIRCEP.110.960658.PubMedCentralCrossRefPubMed Panikkath R, Reinier K, Uy-Evanado A, Teodorescu C, Hattenhauer J, Mariani R, Gunson K, Jui J, Chugh SS: Prolonged Tpeak-to-tend interval on the resting ECG is associated with increased risk of sudden cardiac death. Circ Arrhythm Electrophysiol. 2011, 4: 441-447. 10.1161/CIRCEP.110.960658.PubMedCentralCrossRefPubMed
22.
go back to reference Mitsumata K, Saitoh S, Ohnishi H, Akasaka H, Miura T: Effects of parental hypertension on longitudinal trends in blood pressure and plasma metabolic profile: mixed-effects model analysis. Hypertension. 2012, 60: 1124-1130. 10.1161/HYPERTENSIONAHA.112.201129.CrossRefPubMed Mitsumata K, Saitoh S, Ohnishi H, Akasaka H, Miura T: Effects of parental hypertension on longitudinal trends in blood pressure and plasma metabolic profile: mixed-effects model analysis. Hypertension. 2012, 60: 1124-1130. 10.1161/HYPERTENSIONAHA.112.201129.CrossRefPubMed
23.
go back to reference Report and recommendations of the San Antonio conference on diabetic neuropathy. American Diabetes Association American Academy of Neurology. Diabetes Care. 1988, 11: 592-597. Report and recommendations of the San Antonio conference on diabetic neuropathy. American Diabetes Association American Academy of Neurology. Diabetes Care. 1988, 11: 592-597.
24.
go back to reference Takebayashi K, Sugita R, Tayama K, Aso Y, Takemura Y, Inukai T: The connection between QT dispersion and autonomic neuropathy in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes. 2003, 111: 351-357. 10.1055/s-2003-42726.CrossRefPubMed Takebayashi K, Sugita R, Tayama K, Aso Y, Takemura Y, Inukai T: The connection between QT dispersion and autonomic neuropathy in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes. 2003, 111: 351-357. 10.1055/s-2003-42726.CrossRefPubMed
25.
go back to reference Rautaharju PM, Zhang ZM: Linearly scaled, rate-invariant normal limits for QT interval: eight decades of incorrect application of power functions. J Cardiovasc Electrophysiol. 2002, 13: 1211-1218. 10.1046/j.1540-8167.2002.01211.x.CrossRefPubMed Rautaharju PM, Zhang ZM: Linearly scaled, rate-invariant normal limits for QT interval: eight decades of incorrect application of power functions. J Cardiovasc Electrophysiol. 2002, 13: 1211-1218. 10.1046/j.1540-8167.2002.01211.x.CrossRefPubMed
26.
go back to reference Rautaharju PM, Surawicz B, Gettes LS, Bailey JJ, Childers R, Deal BJ, Gorgels A, Hancock EW, Josephson M, Kligfield P, Kors JA, Macfarlane P, Mason JW, Mirvis DM, Okin P, Pahlm O, van Herpen G, Wagner GS, Wellens H: AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part IV: the ST segment, T and U waves, and the QT interval: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiology. J Am Coll Cardiol. 2009, 53: 982-991. 10.1016/j.jacc.2008.12.014.CrossRefPubMed Rautaharju PM, Surawicz B, Gettes LS, Bailey JJ, Childers R, Deal BJ, Gorgels A, Hancock EW, Josephson M, Kligfield P, Kors JA, Macfarlane P, Mason JW, Mirvis DM, Okin P, Pahlm O, van Herpen G, Wagner GS, Wellens H: AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part IV: the ST segment, T and U waves, and the QT interval: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiology. J Am Coll Cardiol. 2009, 53: 982-991. 10.1016/j.jacc.2008.12.014.CrossRefPubMed
27.
go back to reference Festa A, D’Agostino R, Rautaharju P, Mykkänen L, Haffner SM: Relation of systemic blood pressure, left ventricular mass, insulin sensitivity, and coronary artery disease to QT interval duration in nondiabetic and type 2 diabetic subjects. Am J Cardiol. 2000, 86: 1117-1122. 10.1016/S0002-9149(00)01170-X.CrossRefPubMed Festa A, D’Agostino R, Rautaharju P, Mykkänen L, Haffner SM: Relation of systemic blood pressure, left ventricular mass, insulin sensitivity, and coronary artery disease to QT interval duration in nondiabetic and type 2 diabetic subjects. Am J Cardiol. 2000, 86: 1117-1122. 10.1016/S0002-9149(00)01170-X.CrossRefPubMed
28.
go back to reference Tekin A, Tekin G, Sezgin AT, Müderrisoğlu H: Short- and long-term effect of simvastatin therapy on the heterogeneity of cardiac repolarization in diabetic patients. Pharmacol Res. 2008, 57: 393-397. 10.1016/j.phrs.2008.04.001.CrossRefPubMed Tekin A, Tekin G, Sezgin AT, Müderrisoğlu H: Short- and long-term effect of simvastatin therapy on the heterogeneity of cardiac repolarization in diabetic patients. Pharmacol Res. 2008, 57: 393-397. 10.1016/j.phrs.2008.04.001.CrossRefPubMed
29.
go back to reference Veglio M, Chinaglia A, Cavallo-Perin P: QT interval, cardiovascular risk factors and risk of death in diabetes. J Endocrinol Invest. 2004, 27: 175-181. 10.1007/BF03346265.CrossRefPubMed Veglio M, Chinaglia A, Cavallo-Perin P: QT interval, cardiovascular risk factors and risk of death in diabetes. J Endocrinol Invest. 2004, 27: 175-181. 10.1007/BF03346265.CrossRefPubMed
30.
go back to reference Psallas M, Tentolouris N, Papadogiannis D, Doulgerakis D, Kokkinos A, Cokkinos DV, Katsilambros N: QT dispersion: comparison between participants with Type 1 and 2 diabetes and association with microalbuminuria in diabetes. J Diabetes Complications. 2006, 20: 88-97. 10.1016/j.jdiacomp.2005.05.012.CrossRefPubMed Psallas M, Tentolouris N, Papadogiannis D, Doulgerakis D, Kokkinos A, Cokkinos DV, Katsilambros N: QT dispersion: comparison between participants with Type 1 and 2 diabetes and association with microalbuminuria in diabetes. J Diabetes Complications. 2006, 20: 88-97. 10.1016/j.jdiacomp.2005.05.012.CrossRefPubMed
31.
go back to reference Giunti S, Bruno G, Lillaz E, Gruden G, Lolli V, Chaturvedi N, Fuller JH, Veglio M, Cavallo-Perin P: Incidence and risk factors of prolonged QTc interval in type 1 diabetes: the EURODIAB Prospective Complications Study. Diabetes Care. 2007, 30: 2057-2063. 10.2337/dc07-0063.CrossRefPubMed Giunti S, Bruno G, Lillaz E, Gruden G, Lolli V, Chaturvedi N, Fuller JH, Veglio M, Cavallo-Perin P: Incidence and risk factors of prolonged QTc interval in type 1 diabetes: the EURODIAB Prospective Complications Study. Diabetes Care. 2007, 30: 2057-2063. 10.2337/dc07-0063.CrossRefPubMed
32.
go back to reference Suys B, Heuten S, De Wolf D, Verherstraeten M, de Beeck LO, Matthys D, Vrints C, Rooman R: Glycemia and corrected QT interval prolongation in young type 1 diabetic patients: what is the relation?. Diabetes Care. 2006, 29: 427-429. 10.2337/diacare.29.02.06.dc05-1450.CrossRefPubMed Suys B, Heuten S, De Wolf D, Verherstraeten M, de Beeck LO, Matthys D, Vrints C, Rooman R: Glycemia and corrected QT interval prolongation in young type 1 diabetic patients: what is the relation?. Diabetes Care. 2006, 29: 427-429. 10.2337/diacare.29.02.06.dc05-1450.CrossRefPubMed
33.
go back to reference Najeed SA, Khan IA, Molnar J, Somberg JC: Differential effect of glyburide (glibenclamide) and metformin on QT dispersion: a potential adenosine triphosphate sensitive K + channel effect. Am J Cardiol. 2002, 90: 1103-1106. 10.1016/S0002-9149(02)02776-5.CrossRefPubMed Najeed SA, Khan IA, Molnar J, Somberg JC: Differential effect of glyburide (glibenclamide) and metformin on QT dispersion: a potential adenosine triphosphate sensitive K + channel effect. Am J Cardiol. 2002, 90: 1103-1106. 10.1016/S0002-9149(02)02776-5.CrossRefPubMed
34.
go back to reference Bloomfield DM, Krishna R, Hreniuk D, Hickey L, Ghosh K, Bergman AJ, Miller J, Gutierrez MJ, Stoltz R, Gottesdiener KM, Herman GA, Wagner JA: A thorough QTc study to assess the effect of sitagliptin, a DPP4 inhibitor, on ventricular repolarization in healthy subjects. J Clin Pharmacol. 2009, 49: 937-946. 10.1177/0091270009337511.CrossRefPubMed Bloomfield DM, Krishna R, Hreniuk D, Hickey L, Ghosh K, Bergman AJ, Miller J, Gutierrez MJ, Stoltz R, Gottesdiener KM, Herman GA, Wagner JA: A thorough QTc study to assess the effect of sitagliptin, a DPP4 inhibitor, on ventricular repolarization in healthy subjects. J Clin Pharmacol. 2009, 49: 937-946. 10.1177/0091270009337511.CrossRefPubMed
35.
go back to reference Ring A, Brand T, Macha S, Breithaupt-Groegler K, Simons G, Walter B, Woerle HJ, Broedl UC: The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study. Cardiovasc Diabetol. 2013, 12: 70-10.1186/1475-2840-12-70.PubMedCentralCrossRefPubMed Ring A, Brand T, Macha S, Breithaupt-Groegler K, Simons G, Walter B, Woerle HJ, Broedl UC: The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study. Cardiovasc Diabetol. 2013, 12: 70-10.1186/1475-2840-12-70.PubMedCentralCrossRefPubMed
36.
go back to reference Geisen K, Végh A, Krause E, Papp JG: Cardiovascular effects of conventional sulfonylureas and glimepiride. Horm Metab Res. 1996, 28: 496-507. 10.1055/s-2007-979841.CrossRefPubMed Geisen K, Végh A, Krause E, Papp JG: Cardiovascular effects of conventional sulfonylureas and glimepiride. Horm Metab Res. 1996, 28: 496-507. 10.1055/s-2007-979841.CrossRefPubMed
37.
go back to reference Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA: 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008, 359: 1577-1589. 10.1056/NEJMoa0806470.CrossRefPubMed Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA: 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008, 359: 1577-1589. 10.1056/NEJMoa0806470.CrossRefPubMed
38.
go back to reference Karpanou EA, Vyssoulis GP, Psichogios A, Malakou C, Kyrozi EA, Cokkinos DV, Toutouzas PK: Regression of left ventricular hypertrophy results in improvement of QT dispersion in patients with hypertension. Am Heart J. 1998, 136: 765-768. 10.1016/S0002-8703(98)70119-X.CrossRefPubMed Karpanou EA, Vyssoulis GP, Psichogios A, Malakou C, Kyrozi EA, Cokkinos DV, Toutouzas PK: Regression of left ventricular hypertrophy results in improvement of QT dispersion in patients with hypertension. Am Heart J. 1998, 136: 765-768. 10.1016/S0002-8703(98)70119-X.CrossRefPubMed
39.
go back to reference Fogari R, Zoppi A, Maffioli P, Monti C, Lazzari P, Mugellini A, Derosa G: Effects of aliskiren on QT duration and dispersion in hypertensive patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2012, 14: 341-347. 10.1111/j.1463-1326.2011.01535.x.CrossRefPubMed Fogari R, Zoppi A, Maffioli P, Monti C, Lazzari P, Mugellini A, Derosa G: Effects of aliskiren on QT duration and dispersion in hypertensive patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2012, 14: 341-347. 10.1111/j.1463-1326.2011.01535.x.CrossRefPubMed
40.
go back to reference Gaede P, Lund-Andersen H, Parving HH, Pedersen O: Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008, 358: 580-591. 10.1056/NEJMoa0706245.CrossRefPubMed Gaede P, Lund-Andersen H, Parving HH, Pedersen O: Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008, 358: 580-591. 10.1056/NEJMoa0706245.CrossRefPubMed
41.
go back to reference Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C: Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008, 371: 117-125. 10.1016/S0140-6736(08)60761-8.CrossRefPubMed Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C: Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008, 371: 117-125. 10.1016/S0140-6736(08)60761-8.CrossRefPubMed
42.
go back to reference Hanefeld M, Duetting E, Bramlage P: Cardiac implications of hypoglycaemia in patients with diabetes - a systematic review. Cardiovasc Diabetol. 2013, 12: 135-10.1186/1475-2840-12-135.PubMedCentralCrossRefPubMed Hanefeld M, Duetting E, Bramlage P: Cardiac implications of hypoglycaemia in patients with diabetes - a systematic review. Cardiovasc Diabetol. 2013, 12: 135-10.1186/1475-2840-12-135.PubMedCentralCrossRefPubMed
43.
go back to reference Chow E, Bernjak A, Williams S, Fawdry RA, Hibbert S, Freeman J, Sheridan PJ, Heller SR: Risk of cardiac arrhythmias during hypoglycemia in patients with type 2 diabetes and cardiovascular risk. Diabetes. 2014, 63: 1738-1747. 10.2337/db13-0468.CrossRefPubMed Chow E, Bernjak A, Williams S, Fawdry RA, Hibbert S, Freeman J, Sheridan PJ, Heller SR: Risk of cardiac arrhythmias during hypoglycemia in patients with type 2 diabetes and cardiovascular risk. Diabetes. 2014, 63: 1738-1747. 10.2337/db13-0468.CrossRefPubMed
44.
go back to reference Beom JW, Kim JM, Chung EJ, Kim JY, Ko SY, Na SD, Kim CH, Park G, Kang MY: Corrected QT interval prolongation during severe hypoglycemia without hypokalemia in patients with type 2 diabetes. Diabetes Metab J. 2013, 37: 190-195. 10.4093/dmj.2013.37.3.190.PubMedCentralCrossRefPubMed Beom JW, Kim JM, Chung EJ, Kim JY, Ko SY, Na SD, Kim CH, Park G, Kang MY: Corrected QT interval prolongation during severe hypoglycemia without hypokalemia in patients with type 2 diabetes. Diabetes Metab J. 2013, 37: 190-195. 10.4093/dmj.2013.37.3.190.PubMedCentralCrossRefPubMed
45.
go back to reference Ling S, Nguyen HT: Ventricular repolarization variability for hypoglycemia detection. Conf Proc IEEE Eng Med Biol Soc. 2011, 2011: 7961-7964.PubMed Ling S, Nguyen HT: Ventricular repolarization variability for hypoglycemia detection. Conf Proc IEEE Eng Med Biol Soc. 2011, 2011: 7961-7964.PubMed
Metadata
Title
Does glycemic control reverse dispersion of ventricular repolarization in type 2 diabetes?
Authors
Takayuki Miki
Toshiyuki Tobisawa
Tatsuya Sato
Masaya Tanno
Toshiyuki Yano
Hiroshi Akasaka
Atsushi Kuno
Makoto Ogasawara
Hiromichi Murase
Shigeyuki Saitoh
Tetsuji Miura
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2014
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/s12933-014-0125-8

Other articles of this Issue 1/2014

Cardiovascular Diabetology 1/2014 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.